Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and
Strengthened Clinical and Regulatory Leadership Team with Key AppointmentsStart-up Activities for the Global Phase 3 Trial Ongoing with Release of Drug Product Manufactured with Commercial Process and First Patient Expected to be Dosed in 2H 2023BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinic...
Source: pharmiweb.com